OncoCyte Earnings Call: GraftAssureDx Drives Pivot

OncoCyte Corp ((IMDX)) has held its Q4 earnings call. Read on for the main highlights of the call.

OncoCyte’s latest earnings call carried a cautiously upbeat tone as management highlighted major regulatory and strategic wins around its GraftAssureDx transplant test while openly flagging near‑term revenue softness and higher cash burn. Executives framed 2024 as a pivotal investment and execution year, with funding secured and a clearer commercialization roadmap, but acknowledged reimbursement and adoption risks that investors will need to monitor.

FDA Submission Positions GraftAssureDx for Commercial Launch

The company underscored the FDA submission of GraftAssureDx as a watershed moment, calling it the first dd‑cfDNA assay to seek FDA authorization. This regulatory milestone pivots OncoCyte from pure development to launch readiness, with the team now focused on navigating review and building the infrastructure required for commercialization later this year.

GALACTIC Registry Builds Clinical Footprint

Management reported strong momentum in the GALACTIC registry, with 28 centers already in the process of becoming trial sites toward a goal of about 50. Overall, 37 U.S. transplant centers are now engaged, and the registry aims for roughly 5,000 patients and around 10 tests per patient, creating a rich clinical dataset and early user base.

Head-to-Head Data Boosts Credibility and Early Adoption

A leading transplant center presented head‑to‑head data on more than 140 patient samples showing GraftAssure performance equivalent to that of a national reference lab. That institution now plans to bring GraftAssure into its core lab, a move that provides influential third‑party validation and is expected to spur additional comparative studies and wider institutional interest.

Commercial Build-Out Targets Accelerated Center Engagement

OncoCyte is investing ahead of revenue, adding targeted roles in clinical and technical sales as well as medical and clinical affairs to deepen its presence in transplant centers. Management signaled that hiring will ramp further as FDA authorization nears, seeking to smooth the commercialization curve and support both registry enrollment and in‑house adoption.

Financing Strengthened by Strategic Investor Participation

The company completed a $26 million registered direct offering that extended its runway for both commercial launch and R&D expansion. Notably, Bio‑Rad took part and now owns just under 10%, reinforcing its strategic alignment with OncoCyte’s transplant focus and signaling external confidence in the GraftAssure platform.

U.S. Reimbursement Pathway Gains Definition

Management highlighted a clear initial reimbursement footing, citing a Medicare rate of $27.53 per GraftAssure test. OncoCyte has applied for a MolDx Z‑code for its regulated kitted test and is running a bridging study to align kitted reimbursement with its current lab‑developed test, aiming to ease in‑house adoption across MolDx regions.

Organ-Agnostic Platform Underpins Heart Transplant Expansion

GraftAssure is being positioned as organ‑agnostic, with a near‑term push into heart transplantation to expand its addressable market. The company plans a roughly 150‑patient study across four to five heart centers and is targeting a 510(k) submission using an existing transplant assay as predicate, with an expected 90‑day review once filed.

Large Market Opportunity and Center-Based Revenue Model

OncoCyte estimates its total addressable market at more than $2 billion annually, anchored initially in kidney and heart transplants. The commercial model assumes about $1 million in yearly revenue per engaged center, and management noted that maintenance spending of roughly $5.5 million per quarter could be covered at around $35 million in annual revenue if software‑like gross margins are achieved.

Near-Term Revenue Drag from Minimal Lab Services Income

Despite growing clinical traction, the company warned that lab services will add little to the top line in the near term. It expects almost no lab revenue in the first quarter and only modest contributions for the full year, underscoring that meaningful sales depend on FDA authorization and subsequent commercial uptake.

Higher Cash Burn as Investments Are Front-Loaded

OncoCyte raised its quarterly cash burn outlook from roughly $6.0 million to about $7.5 million on average, driven by launch preparation and clinical expansion. Burn is expected to exceed $8.0 million per quarter in the first half before easing back toward approximately $6.0 million in the second half, reflecting timing of spending and payables.

Oncology Write-Down Marks Full Pivot to Transplant

The company recorded an intangible asset write‑down in the fourth quarter tied to its remaining oncology portfolio, which was excluded from adjusted EBITDA. This accounting move formalizes a strategic shift away from oncology toward transplant diagnostics and lowers reported GAAP asset values while sharpening operational focus.

International Reimbursement Remains an Open Question

Outside the United States, OncoCyte is preparing to navigate a more uncertain path, even as technical approvals appear manageable. Management noted that the U.K. can be self‑certified and EU IVDR review could take six to nine months after submission, but reimbursement frameworks in both regions are still unclear and may constrain early revenue.

Execution and Payer Complexity Pose Adoption Risks

Management acknowledged that changing entrenched lab workflows and clinical habits is a non‑trivial hurdle, placing a premium on continued head‑to‑head data and effective sales and medical outreach. The company must also manage a negotiation window with Bio‑Rad around IVD rights and pursue coverage center by center across non‑MolDx territories, adding layers of payer complexity.

Guidance Emphasizes Milestone-Driven 2024 and Investment Phase

Looking ahead, guidance centers on achieving key regulatory and commercial milestones, rather than near‑term profitability or revenue growth. Management is targeting completion of the FDA review for GraftAssure, expansion of the GALACTIC registry to about 50 centers and roughly 50,000 tests, initiation of a heart transplant study and 510(k) filing, while operating with maintenance spend near $5.5 million per quarter, growth spend around $2 million, and elevated cash burn until late‑year normalization.

OncoCyte’s call painted the picture of a company transitioning from R&D story to early commercialization, with GraftAssureDx at the core of its strategy. While investors face a period of limited revenue, higher burn, and reimbursement complexity, the combination of regulatory progress, clinical validation, and fresh capital support an optimistic long‑term narrative—provided the team can execute on launch and drive real-world adoption.